Literature DB >> 33928380

Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19.

Bruna Lo Sasso1,2, Caterina Maria Gambino1, Nicola Scichilone3, Rosaria Vincenza Giglio1, Giulia Bivona1, Concetta Scazzone1, Roberto Muratore2, Salvatore Milano2, Mario Barbagallo4, Luisa Agnello1, Marcello Ciaccio1,2.   

Abstract

OBJECTIVE: The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19.
METHODS: We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated.
RESULTS: Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3-2.95 vs median, 0.82 nmol/L; interquartile range, 0.57-1.03; P <.0001). Receiver operating characteristic curve analysis showed good accuracy of MR-proADM for predicting mortality. A MR-proADM value of 1.73 nmol/L was established as the best cutoff value, with 90% sensitivity and 95% specificity (P <.0001).
CONCLUSION: We found that MR-proADM could represent a prognostic biomarker of COVID-19. © American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; MR-proADM; biomarker; inflammation; respiratory disease

Year:  2021        PMID： 33928380     DOI： 10.1093/labmed/lmab032

Source DB:  PubMed          Journal:  Lab Med        ISSN： 0007-5027


  10 in total

1.  Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine.

Authors:  Bruna Lo Sasso; Luisa Agnello; Rosaria Vincenza Giglio; Caterina Maria Gambino; Anna Maria Ciaccio; Matteo Vidali; Marcello Ciaccio
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

Review 2.  Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.

Authors:  Toshihiro Kita; Kazuo Kitamura
Journal:  Hypertens Res       Date:  2022-01-06       Impact factor: 5.528

3.  Toward finding the difference between untreated celiac disease and COVID-19 infected patients in terms of CD4, CD25 (IL-2 Rα), FOXP3 and IL-6 expressions as genes affecting immune homeostasis.

Authors:  Nastaran Asri; Ehsan Nazemalhosseini Mojarad; Hamed Mirjalali; Seyed Reza Mohebbi; Kaveh Baghaei; Mohammad Rostami-Nejad; Abbas Yadegar; Mostafa Rezaei-Tavirani; Hamid Asadzadeh Aghdaei; Kamran Rostami; Andrea Masotti
Journal:  BMC Gastroenterol       Date:  2021-12-11       Impact factor: 3.067

4.  Mid-Regional Pro-Adrenomedullin, Methemoglobin and Carboxyhemoglobin as Prognosis Biomarkers in Critically Ill Patients with COVID-19: An Observational Prospective Study.

Authors:  Crhistian-Mario Oblitas; Francisco Galeano-Valle; Jesús Ramírez-Navarro; Jorge López-Cano; Ángel Monterrubio-Manrique; Mercedes García-Gámiz; Milagros Sancho-González; Sara Arenal-López; Luis-Antonio Álvarez-Sala Walther; Pablo Demelo-Rodríguez
Journal:  Viruses       Date:  2021-12-06       Impact factor: 5.048

Review 5.  Proadrenomedullin in the Management of COVID-19 Critically Ill Patients in Intensive Care Unit: A Systematic Review and Meta-Analysis of Evidence and Uncertainties in Existing Literature.

Authors:  Giorgia Montrucchio; Eleonora Balzani; Davide Lombardo; Alice Giaccone; Anna Vaninetti; Giulia D'Antonio; Francesca Rumbolo; Giulio Mengozzi; Luca Brazzi
Journal:  J Clin Med       Date:  2022-08-04       Impact factor: 4.964

6.  Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.

Authors:  Eun-Hee Nah; Seon Cho; Hyeran Park; Suyoung Kim; Dongwon Noh; Eunjoo Kwon; Han-Ik Cho
Journal:  J Med Virol       Date:  2022-06-14       Impact factor: 20.693

7.  Prognostic value of proadrenomedullin in patients with COVID-19 pneumonia.

Authors:  Aleksandr A Astapovskii; Vladimir N Drozdov; Evgenia V Shikh; George G Melkonyan; Zhanna M Sizova; Valeria L Zakharova; Natalia N Shindryaeva; Natalia I Lapidus
Journal:  Front Med (Lausanne)       Date:  2022-08-22

8.  Plasma Levels of Mid-Regional Proadrenomedullin Accurately Identify H1N1pdm09 Influenza Virus Patients with Risk of Intensive Care Admission and Mortality in the Emergency Department.

Authors:  Blanca Valenzuela-Méndez; Francisco Valenzuela-Sánchez; Juan Francisco Rodríguez-Gutiérrez; Rafael Bohollo-de-Austria; Ángel Estella; Pilar Martínez-García; María Ángela González-García; Jordi Rello
Journal:  J Pers Med       Date:  2022-01-10

Review 9.  Adrenomedullin Therapy in Moderate to Severe COVID-19.

Authors:  Toshihiro Kita; Kazuo Kitamura
Journal:  Biomedicines       Date:  2022-02-24

Review 10.  Biomarkers Associated with Cardiovascular Disease in COVID-19.

Authors:  Christoph C Kaufmann; Amro Ahmed; Achim Leo Burger; Marie Muthspiel; Bernhard Jäger; Johann Wojta; Kurt Huber
Journal:  Cells       Date:  2022-03-08       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.